Pancreatic secretory trypsin inhibitor (PSTI) is expressed in most bladder
carcinomas, where its pathophysiological relevance is unclear. Using recombinant normal sequence PSTI/
tumor-associated trypsin inhibitor (TATI), a variant associated with
familial pancreatitis (N34S), an active site-inactivated variant (R18/V19), and immunoneutralization and RNA interference-mediated knockdown techniques, we investigated the actions of PSTI/TATI on cell migration (wounding monolayers),
collagen invasion (gel invasion assays), and proliferation (
Alamar blue) on 253J, RT4, and HT1376 human bladder
carcinoma cell lines. All three forms of PSTI/TATI stimulated migration twofold, and normal sequence PSTI/TATI showed synergistic promigratory effects when added with
EGF. Addition of structurally unrelated soybean
trypsin inhibitor had no promigratory activity. Similar results were seen using
collagen invasion assays, although the active site mutated variant had no proinvasive activity, probably due to reduced Akt2 activation. PSTI/TATI did not stimulate proliferation despite acting, at least partially, through the
EGF receptor, as effects of PSTI/TATI were truncated by the addition of an
EGF receptor blocking antibody or the
tyrosine kinase inhibitor tyrphostin. Cell lines produced endogenous PSTI/TATI, and PSTI/TATI RNA interference knockdown or the addition of PSTI/TATI,
EGF receptor, or
tyrphostin blocking agents reduced migration and invasion below baseline. PSTI/TATI induced phosphorylation of the
EGF receptor, ERK1 and ERK2, Akt2 and Akt3, JNK1, MKK3, and
ribosomal protein S6 kinase 1. This profile was more limited than that induced by
EGF and did not include Akt1, probably explaining the lack of proproliferative activity. Our findings of autocrine stimulation and synergistic responses between
EGF and PSTI/TATI at concentrations found in urine and tissue suggest that PSTI/TATI has pathophysiological relevance.